Compare Recursion Pharmaceuticals Inc (RXRX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Shell PLC — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while Shell PLC trades at $100.15 (market cap $284.34B). The key difference: Shell PLC is far larger — about 132.9× Recursion Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Shell PLC for 90 Days on average.
| RXRX | SHEL | |
|---|---|---|
Market Cap | $2.14B | $284.34B |
Volume | 30,789,535 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $6.79 | $100.20 |
52-Week Low | $2.84 | $70.31 |
Typical Hold Time | 22 Days | 90 Days |
Enterprise Value | $1.66B | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Shell (SHEL) trades at $96.85, down 0.79% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company's valuation ratios are attractive, with a P/E of 11.08 and P/S of 0.97, while profitability metrics like a 14.35% ROE and 8.76% net margin reflect solid fundamentals. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, positioning Shell for long-term growth in energy transition markets.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, but risks involve volatile oil prices and execution challenges in new projects. The stock offers value with upside potential, though investors should monitor energy market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
